BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 7, 2007
View Archived Issues
Trials assessing the efficacy of drugs for restless legs syndrome
Read More
Preclinical activity of the novel Aurora kinase inhibitor AZD-1152 profiled at the AACR meeting
Read More
Novel antiinflammatory agents disclosed in recent patents
Read More
Effects of NGX-4010 assessed in HIV-associated distal sensory polyneuropathy
Read More
New preclinical data on GSK-923295 reported by GSK and Cytokinetics
Read More
Recent patent from Astellas describes novel xanthine oxidase inhibitors
Read More
Recent patents disclose new therapeutic agents for anxiety and depression
Read More
Preclinical findings on the anti-DR5 agonist antibody LBY-135 reported by Novartis
Read More
Potent antitumor and antiangiogenic activity of LP-261 alone or in combination with bevacizumab
Read More
Platencin shows antibiotic activity in vivo via inhibition of fatty acid biosynthesis
Read More
Purdue Research Foundation licenses flu vaccine candidate to PaxVax
Read More
CyDex licenses Captisol enabling technology to Proteolix
Read More
Second phase III study begins for OPT-80 in CDAD
Read More
Sapacitabine studied in new phase II trial for advanced CTCL
Read More
Iplex demonstrates efficacy in HARS
Read More
NGD-4715 for obesity completes first-in-man study
Read More
Study establishes proof of concept for PRO-140 as antiretroviral agent
Read More
Oral cethromycin 100% protective against lethal dose of inhaled anthrax
Read More
A novel SIRT1 activator from Sirtris shows neuroprotective effects in optic neuritis in vivo
Read More
In vivo antiangiogenic activity of Immusol's new compound, IMS-2186
Read More
6R-BH4 enters phase IIa study for sickle cell disease
Read More
Treatment complete in phase III study of TH-9507 in HIV-associated lipodystrophy
Read More
Expression Genetics receives grant for development of EGEN-001 in ovarian cancer
Read More
PrimoVax study of GV-1001 cleared to open in U.S.
Read More
Quest advances SL-052 for prostate cancer in preclinical testing
Read More
Pivotal trials begin for EOquin in noninvasive bladder cancer
Read More
Lux receives Canadian clearance for phase II/III trials of LX-211 in uveitis
Read More
IND clearance for study of allogeneic adult stem cells in heart attack patients
Read More
Vyvanse receives DEA schedule classification
Read More
Ista receives non approvable letter for T-Pred
Read More